We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Noninfringement Finding In Biologics Dispute Affirmed By Panel

Mealey's (May 9, 2019, 12:21 PM EDT) -- WASHINGTON, D.C. — A California federal judge’s determination that a Sandoz Inc. filgrastim biosimilar and proposed pegfilgrastim biosimilar product do not infringe an Amgen patent relating to Neupogen and Neulasta was...
To view the full article, register now.